Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUILD UC
2017-002108-28Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Dekavil + infliximab with Placebo + infliximab (2 arms). Primary endpoint: Clinical remission at Week 12. Started Mar 2018; status: completed.
02
Drugs
f8il10
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-002108-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002108-28.